Evidence map›Paper›PMID 42161432›Full record

ArticleLupus science & medicine2026

Comparison of aspirin and rivaroxaban for the prevention of pulmonary embolism and deep vein thrombosis in high thrombotic risk patients with systemic lupus erythematosus: study protocol for a multicentre, prospective, randomised controlled trial.

Zixi Zhang, Fen Li, Yasong Li, Zhengquan Xie, Jinfeng Du, Ni Mao, Shu Li, Yiming Liu, Yan Ge, Jia Wang and 10 more

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Lupus science & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Zixi ZhangDepartment of Cardiology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Fen LiDepartment of Rheumatology and Immunology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Yasong LiDepartment of Rheumatology and Immunology, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China.
Zhengquan XieDepartment of Rheumatology and Immunology, Panyu Hospital of Traditional Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
Jinfeng DuDepartment of Rheumatology and Immunology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Ni MaoDepartment of Rheumatology and Immunology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Shu LiDepartment of Rheumatology and Immunology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Yiming LiuDepartment of Rheumatology and Immunology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Yan GeDepartment of Rheumatology and Immunology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Jia WangDepartment of Rheumatology and Immunology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Qi TangDepartment of Rheumatology and Immunology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Jin KangDepartment of Rheumatology and Immunology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Xiaofei PengDepartment of Rheumatology and Immunology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Wei ChengDepartment of Rheumatology and Immunology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Yixi LiDepartment of Rheumatology and Immunology, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China.
Pengfei XuDepartment of Rheumatology and Immunology, Panyu Hospital of Traditional Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
Yichao XiaoDepartment of Cardiology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Tao TuDepartment of Cardiology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Xi XieDepartment of Rheumatology and Immunology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China qimingliu@csu.edu.cn hsixie1997@csu.edu.cn.
Qiming LiuDepartment of Cardiology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China qimingliu@csu.edu.cn hsixie1997@csu.edu.cn.ORCID 0000-0003-0282-4313

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThromboembolic events are an important cause of morbidity and mortality in systemic lupus erythematosus (SLE). Current thromboprophylaxis recommendations mainly focus on patients with antiphospholipid syndrome or persistent antiphospholipid antibody (aPL) positivity, whereas preventive strategies for aPL-negative patients with elevated thrombotic risk remain poorly defined. D-dimer elevation is common in SLE and has been associated with an increased risk of venous thromboembolism (VTE), but its role in guiding preventive anticoagulation remains uncertain. METHODS AND ANALYSIS: ETHICS AND DISSEMINATION: The study has been approved by the Biomedical Research Ethics Committee of the Second Xiangya Hospital, Central South University (approval number: LYEC2025-K0180) and will be conducted in accordance with the Declaration of Helsinki. The findings will be disseminated through peer-reviewed publication and academic conferences. TRIAL REGISTRATION NUMBER: ChiCTR2600117175.

Indexed as

AspirinLupus Erythematosus, SystemicPulmonary EmbolismRivaroxabanVenous ThrombosisAdultFactor Xa InhibitorsFemaleFibrin Fibrinogen Degradation ProductsHumansMaleMiddle AgedMulticenter Studies as TopicProspective StudiesRandomized Controlled Trials as TopicAspirinFactor Xa InhibitorsFibrin Fibrinogen Degradation Productsfibrin fragment DRivaroxabanAdaptive Clinical Trial DesignAntibodies, AnticardiolipinAntibodies, AntiphospholipidAutoimmune DiseasesLupus Erythematosus, Systemic

Identifiers

PMID42161432
PMCPMC13202078

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.